Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2026)

Recursion Pharmaceuticals' Intangibles history runs 7 years deep, the most recent figure standing at $294.1 million for Q1 2026.

• Quarterly Intangibles fell 12.42% year-over-year to $294.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $294.1 million (down 12.42% YoY) and the FY2025 annual result came in at $309.9 million, down 7.73% from the prior year.
• Intangibles was $294.1 million for Q1 2026 at Recursion Pharmaceuticals, down from $309.9 million in the prior quarter.
• Across five years, Intangibles topped out at $341.3 million in Q2 2025 and bottomed at $1.2 million in Q2 2022.
• A 5-year average of $127.6 million and a median of $38.2 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2023 — Intangibles soared 3367.72% — and 2024, when it decreased 13.6%.
• Recursion Pharmaceuticals' Intangibles stood at $1.3 million in 2022, then surged by 2690.43% to $36.4 million in 2023, then jumped by 821.59% to $335.9 million in 2024, then dropped by 7.73% to $309.9 million in 2025, then declined by 5.11% to $294.1 million in 2026.
• Business Quant data shows RXRX's Intangibles at $294.1 million in Q1 2026, $309.9 million in Q4 2025, and $322.3 million in Q3 2025.